TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02999360

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Background Music
Description: 30 minutes background music only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: There will be three blocks of treatment and the AE will take place for all participants during one or two treatment blocks (randomly assigned), threetimes a week (sessions are three times a week prior to speech therapy but may be one or two times a week if a session is missed or may be up to four or five times a week if one or two sessions are missed and rescheduled due to weather or other circumstances).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: There will be three blocks of treatment and the AE will take place for all participants during one or two treatment blocks (randomly assigned), threetimes a week (sessions are three times a week prior to speech therapy but may be one or two times a week if a session is missed or may be up to four or five times a week if one or two sessions are missed and rescheduled due to weather or other circumstances).
Study: NCT03249558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine
Description: Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
Study: NCT01784549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin Docetaxel Gefitinib Pemetrexed Vinorelbine Gemcitabine
Study: NCT00759473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine (DCS)
Description: 50 mg d-cycloserine or placebo taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine (DCS)
Description: 50 mg d-cycloserine or placebo taken orally

Intervention type: DRUG
Group type: OTHER
Intervention: D-Cycloserine (DCS)
Description: 50 mg d-cycloserine or placebo taken orally
Study: NCT03927846

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurse-guided Web-based Cognitive Behavioral Therapy
Description: nurse contact is to support and enhance participants' motivation to engage in the web-based CBT program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurse-guided Web-based Cognitive Behavioral Therapy
Description: nurse contact is to support and enhance participants' motivation to engage in the web-based CBT program.
Study: NCT03680131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EB01 Cream Placebo
Description: Vehicle Cream containing 0% EB w/w applied BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EB01 Cream 0.2%
Description: EB01 Cream containing 0.2% EB01 w/w applied BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EB01 Cream 1.0%
Description: EB01 Cream containing 1.0% EB01 w/w applied BID
Study: NCT00759473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03344497

Intervention type: OTHER
Group type: OTHER
Intervention: VC Group
Description: VC (Conventional Consultation/Video) Group
Study: NCT03687034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Standard-of-care chemotherapy for patients with glioblastoma includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body- surface area per day, seven days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for five days during each 28-day cycle).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune
Description: Standard-of-care treatment for glioblastoma includes alternating electric-field therapy, or Optune, as a Category 1 treatment in conjunction with temozolomide after maximal safe resection and completion of radiation therapy.
Study: NCT02760407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olokizumab 64mg q4w
Description: 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olokizumab 64mg q2w
Description: 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab 40mg q2w
Description: 0.4 or 0.8 mL prefilled, single-dose syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo q2w
Description: sodium chloride 0.9% solution supplied in either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo q2w
Description: sodium chloride 0.9% solution supplied in either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
Study: NCT01112215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Initial dose of 2-2.5 mg/kg (according to TMTP levels) for 6 months according the severity of the flare with progressive tapering if complete remission has been obtained

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric-Coated Mycophenolate Sodium
Description: Initial dose of 1440 mg/day for 6 months to be tapered progressively if complete remission had been obtained
Study: NCT00060086

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pomegranate juice
Description: Subjects receive oral pomegranate juice once daily. Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity.
Study: NCT00323258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Letter to physician/discharge summary
Description: A letter/discharge summary from the hospital physician to the community physician listing the discharge medications, procedures, and recommendations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Letter to physician/discharge summary
Description: A letter/discharge summary from the hospital physician to the community physician listing the discharge medications, procedures, and recommendations.
Study: NCT03958812

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating tumor cells, Volatile organic compounds
Description: Alveolar exhaled breath samples and peripheral venous blood(10ml) will be collected from each patients

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating tumor cells, Volatile organic compounds
Description: Alveolar exhaled breath samples and peripheral venous blood(10ml) will be collected from each patients

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating tumor cells, Volatile organic compounds
Description: Alveolar exhaled breath samples and peripheral venous blood(10ml) will be collected from each patients

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating tumor cells, Volatile organic compounds
Description: Alveolar exhaled breath samples and peripheral venous blood(10ml) will be collected from each patients

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating tumor cells, Volatile organic compounds
Description: Alveolar exhaled breath samples and peripheral venous blood(10ml) will be collected from each patients
Study: NCT04353986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Ledipasvir
Description: fixed dose tablet containing 400 mg sofosbuvir and 90 mg ledipasvir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir and Ledipasvir
Description: fixed dose tablet containing 400 mg sofosbuvir and 90 mg ledipasvir
Study: NCT02095613

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional food

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: food that is nutrient dense
Study: NCT00031707

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: eicosapentaenoic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: eicosapentaenoic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: megestrol acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: megestrol acetate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study: NCT03341013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 Formulation 2
Description: Sequence 1 Period 1 and Sequence 2 Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 Formulation 2
Description: Sequence 1 Period 1 and Sequence 2 Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 Formulation 3
Description: Sequence 1 Period 2 and Sequence 2 Period 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 Formulation 3
Description: Sequence 1 Period 2 and Sequence 2 Period 1
Study: NCT01715077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab at 3 mg/kg dose
Study: NCT01732562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient e-Learning educational tool
Description: Web based site with videos of TKR surgical animation, demonstrations of exercises and activities following surgery and conversations with surgeons, physiotherapist, occupational therapist and patients.
Study: NCT03956420

Intervention type: BEHAVIORAL
Intervention: Premedication visit
Description: detailed information about surgery, anaesthesia and postoperative period

Intervention type: DIETARY_SUPPLEMENT
Intervention: Preoperative period
Description: avoidance of prolonged fasting, intake of fluids with carbohydrates before surgery

Intervention type: DRUG
Intervention: Preoperative period
Description: administration of melatonin 5 mg in the evening and pregabalin 75 mg one hour before entering the operating theatre

Intervention type: OTHER
Intervention: Postoperative period
Description: Fluids 1 ml/kg/h; Discontinuation of propofol at the moment of drainage and cardiovascular system stabilization; Fluids administered orally 2 hours after extubation; Early mobilisation

Intervention type: OTHER
Intervention: Intraoperative period
Description: deep temperature (necessity to maintain normothermia during the stay in the operating theatre 36 °C. Normothermia should be maintained rather than restored.

Intervention type: DRUG
Intervention: Intraoperative period
Description: Pyralgin 1 g i.v. after induction of anaesthesia; in patients allergic to Pyralginum, Perfalgan 1 g i.v.

Intervention type: DRUG
Intervention: Intraoperative period
Description: Ketamine 30 mg i.v. after induction of anaesthesia

Intervention type: DRUG
Intervention: Intraoperative period
Description: Sevoflurane 1.5 MAC higher in patients \< 60 years old

Intervention type: DRUG
Intervention: Intraoperative period
Description: Propofol infusion in patients at risk of postoperative vomiting (Apfel ≥ 2 points), sevoflurane administration at the moments of strong stimuli from the operating field

Intervention type: DRUG
Intervention: Intraoperative period
Description: Continuous infusion of balanced multi-electrolyte fluids 1-3 ml/kg/h
Study: NCT00841659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine HCl
Description: 40 mg Film-Coated Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxil®
Description: 40 mg Film-Coated Tablet
Study: NCT03739502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: The UCB transplant is a type of stem cell transplant used to treat cancer of the blood or lymph glands. The UCB transplant has advantages over other types of transplants such as ease of obtaining the umbilical cord blood, absence of donor risks, reduced risks of contagious infections, and the availability for immediate use. The UCB transplant is also associated with a lower incidence of graft versus host disease, or GvHD (in GvHD, the transplanted graft attacks the recipient organs).~However, UCB as a graft source for a bone marrow transplant has drawbacks related to the limited cell dose available for transplant and defects in homing. Homing is the process of UCB stem cell lodging in the bone marrow. If the homing is not efficient it could delay the re-population of the stem cells (or engraftment), possibly lead to engraftment failure, and delay the rebuilding of the immune system after transplant. This could, in turn, provide a higher risk to infection after the UCB transplant.
Study: NCT01430533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azelaic acid pre foam formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle pre foam formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water
Study: NCT04277793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitored self-guided problem solving
Description: Problem Solving is a behavioral modification intervention focusing on the training of adaptive problem-solving skills in order to cope more effectively with everyday stressful events.
Study: NCT00295490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Devil Claw
Description: Dose ranging study so will elucidate dose Frequency is four times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Devil Claw
Description: Dose ranging study so will elucidate dose Frequency is four times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Devil Claw
Description: Dose ranging study so will elucidate dose Frequency is four times daily
Study: NCT01975831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.
Study: NCT02039440

Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Description: One-time blood draw
Study: NCT02925793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS107

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Study: NCT02885168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Activated Protein C
Description: 24 μg/kg/h during 96 hours - intravenous injection
Study: NCT03680131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EB01 Cream 2.0%
Description: EB01 Cream containing 2.0% EB01 w/w applied BID
Study: NCT06212739

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Diode laser used to effect closure of the anal fistula tract
Study: NCT00295490

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo has same dosing freq as for active intervention and for same time period
Study: NCT02754076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX 250
Description: Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human insulin-like growth factor 2 (rhNAGLU-IGF2)
Study: NCT00949819

Intervention type: OTHER
Intervention: Active surveillance
Description: Serial, long term data collection and active surveillance
Study: NCT06212739

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIFT
Description: The intersphincteric portion of the fistula is excised and ligated.
Study: NCT00894855

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: education about sun protection
Description: This comprehensive education program included a visit with a health educator, on the education van, who gave education about sun safety.
Study: NCT03263351

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education group
Description: Didactic health knowledge about interpersonal violence; basic nutrition guidance; sun safety; depression and signs of suicide; gang violence; substance use.
Study: NCT02727868

Intervention type: GENETIC
Group type: OTHER
Intervention: blood samples

Intervention type: GENETIC
Group type: OTHER
Intervention: blood samples
Study: NCT03978754

Intervention type: DIAGNOSTIC_TEST
Intervention: ICG lymphography、CM、VD、Bioelectrical impedance technology、self-report
Description: All of these methods are used for patients visiting the lymphedema clinic to assess whether they have developed lymphedema.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bioelectrical impedance technology、CM
Description: These two methods are routine evaluation methods for breast cancer patients before surgery
Study: NCT02418299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IncontiLase Er:YAG laser treatment
Description: Each patient will receive 2-3 sessions of Er:YAG laser treatment for stress and mixed urinary incontinence (IncontiLase)
Study: NCT04507672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation
Description: Use the choice of crystalloid for resuscitation during the first 72 hours after enrollment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluid resuscitation
Description: Use the choice of crystalloid for resuscitation during the first 72 hours after enrollment
Study: NCT04016051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin DST (125 mg)
Description: Clarithromycin DST (125.0 mg clarithromycin / straw).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin DST (187.5 mg)
Description: Clarithromycin DST (187.5 mg clarithromycin / straw).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin DST (250 mg)
Description: Clarithromycin DST (250.0 mg clarithromycin / straw).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin Syrup (125 mg)
Description: Clarithromycin Syrup 2.5 ml (125 mg).
Study: NCT03195790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based pediatric obesity treatment
Description: Families with at least one overweight/obese child between ages 6 and 11 years will receive 12-months of family-based pediatric obesity treatment that emphasizes healthy changes to the home environment and family routines. The intervention targets dietary intake, physical activity, and consistent sleep.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-based pediatric obesity treatment
Description: Families with at least one overweight/obese child between ages 6 and 11 years will receive 12-months of family-based pediatric obesity treatment that emphasizes healthy changes to the home environment and family routines. The intervention targets dietary intake, physical activity, and consistent sleep.
Study: NCT01927562

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractyl Duodenal Remodeling System
Study: NCT01631357

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIK cell
Description: CIK cell injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Injection
Description: Gemcitabine injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Injection
Description: Gemcitabine injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin injection
Description: Cisplatin injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin injection
Description: Cisplatin injection